$ADXS news. Keytruda extens length of survival by 2x over current treatments.
03:56 PM EST, 02/13/2020 (MT Newswires) -- Advaxis (ADXS) said on a result update Thursday that its clinical trial investigating ADXS-PSA with Keytruda in patients with metastatic, castrate-resistant prostate cancer showed a median overall survival of 33.7 months in all patients.
Patients with prior visceral metastasis showed a median overall survival of 16.4 months, compared with 11 months on standard of care.
The drug combination "appeared safe and tolerable" in patients enrolled in the study.
Price: 1.04, Change: -0.06, Percent Change: -5.05
http://www.mtnewswires.com Copyright © 2020 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.